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Homocysteine plays an important role in cardiovascular disease as an independent risk factor,
especially in patients with renal insufficiency. The present study aimed to determine whether Hcy
levels, or those of its C677T polymorphism, were associated with higher mortality in patients
submitted to chronic hemodialysis treatment. This was a descriptive, prospective study. Chronic
renal patients undergoing hemodialysis in the "General Hospital, ISSSTE" Dr. Darío Fernández
Fierro, Mexico City were included in the study. Serum homocysteine was analyzed by means of
an ELISA test. The primers utilized for MTHFR C677T polymorphism identification were the
following: F: 5'TGAAGGAGAAGGTGTCTGCGGGA3', R: 5'AGGACGGTGCGGTGAGTG3'
and F2: 5’GCAGGGAGCTTTGAGGCTGAC3’. Differences among nominal conditions were
evaluated by the Mann-Whitney U-test. Spearman test was used for correlation among variables.
Regression, log-linear analysis and receiver operating characteristic (ROC) curves were
conducted to evaluate the possible influence on prognosis of Hcy levels and the presence of the
MTHFR C677T polymorphism. Cox regression and Kaplan-Meier tests were performed to
evaluate the Hcy levels influence on survival. In all cases, p<0.05 was considered statistically
significant. All tests were performed with the SPSS ver. 23 statistical software program. By
means of regression analysis (p = 0.046) and ROC curve age was the sole significant prognostic
variable for the “death”. The loglinear analysis did not show any association between the
presence of MTHFR C677T SNP with the mortality of patients. It was concluded that Hcy levels
and the presence/absence of MTHFR C677T are not stronger predictors for mortality than the
traditional cardiovascular risk factors.
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INTRODUCTION
Homocysteine (Hcy) is a by-product of demethylation
sulfur containing essential amino acid (methionine). It is
metabolized in two different ways: (1) remethylation to
methionine (dependent on vitamin B12 and  folic  acid)  and
(2) transsulfuration to cystathionine (dependent on vitamin
B6)1. While remethylation is the principal determinant of
fasting Hcy   concentrations, transsulfuration remethylation is
responsible for approximately 50% of Hcy metabolism2.
Experimental   studies   have   shown   that
hyperhomocysteinemia may induce proliferation of vascular
smooth muscle cells and endothelial dysfunction by different
mechanisms, such as the production of hydrogen peroxide,
abnormal clotting proteins and hemostatic disorders3-5. In
recent years, a study has shown that Hcy plays an important
role in cardiovascular disease (CVD), associated not only with
other factors, but also as an independent risk factor6.
The CVD is the leading cause of death in patients with
chronic kidney failure7. It is well known that there are several
prevalent risk factors for CVD in kidney failure, for example,
hypertension and dyslipidemia. Moreover, Type 2 diabetes
mellitus (T2DM) is a leading cause of chronic kidney disease
(CKD) and the dialysis population co-exists with hypertension.
Without doubt, Hcy is an independent risk factor for CVD
in general population and plays a leading role in the
development of atherogenesis and vascular thrombosis,
especially in patients with renal insufficiency. In this regard,
patients subjected to hemodialysis are under the toxic effects
of hyperhomocysteinemia8, present in about 85-90% of these
subjects9.
It has been observed that for every 1 mol LG1 of increased
Hcy above normal values (10±5 mM LG1), there is a 3%
increase in mortality in patients on chronic hemodialysis.
Likewise, in chronic kidney failure, hyperhomocysteinemia
occurs more frequently than other cardiovascular risk factors
when compared with general population and in some reports,
it is as high as 83%10,11.
It   is   recognized   that   hyperhomocysteinemia   causes
are  varied  and  include  a  genetic  component  in  which
single nucleotide polymorphisms (SNP) play a key role. In
such, the most studied SNP for its effects on elevated levels of
Hcy  and  the  subsequent  impact  entailed  in  this,  is 
localized in the C677T position of the MTHFR gene, an
enzyme essential in the process of the conversion of Hcy into
methionine12,13.
Multiple  studies14,15  have  shown  that  while
homocysteine levels fall with folic acid, cardiovascular events
and deaths do not decrease. With these data the use of folate in
most patients is discouraged, but doubt remains in patients
with  terminal  CKD.  Despite  this  information,  few  studies
have  been  done  considering  the  presence  of  C677T  SNP
and cardiovascular risk in patients with renal failure. The
principal  aim  of  this study was to assess the role  of  serum
Hcy levels and that of the C677T polymorphism on the
mortality prognosis in patients treated with hemodialysis.
MATERIALS AND METHODS
This was a descriptive, prospective and transversal study
performed at the “Dr. Darío Fernández Fierro” General
Hospital, ISSSTE, Mexico City, from May 1st, 2015-April 30,
2016. Following a convenience sampling, randomly chosen
patients with CKD on hemodialysis replacement therapy with
a minimum of 1 year in the program and an age of >25 years
were enrolled. All of the patients were on dialysis three times
per week through polysulfone membranes and Kt/V was found
at between 1.2 and 1.5. Patients with a history of a previous
cardiovascular event (coronary artery disease (CAD), stroke,
peripheral artery disease, thromboembolic disease and venous
thrombosis) and those with cancer were excluded and those
without Hcy measurements were discarded from the final
analysis.
A survey was conducted on each of the patients to retrieve
information of cardiovascular risk factors, such as alcoholism,
age, drug addiction, gender, low physical activity, smoking
and a familial history. Patients were measured (m) and
weighed (kg) (Torino). Body mass index (BMI) was calculated
as weight (kg) divided by height (m) squared. Blood pressure
was measured with a mercury sphygmomanometer
(Baumanometer, USA) after 5 min of rest.
After a 12 h fasting period, venous blood samples were
taken in Vacutainer™ tubes for determination of creatinine,
glucose, lipid profile, urea, uric acid and blood urea nitrogen
(BUN), (Beckman Coulter AU680) and HbA1c. SerumHcy
was analyzed at the Universidad Colegio Mayor de
Cundinamaca (UCMC), Bogotá, Colombia, by means of an
enzyme-linked   immunosorbent   assay   (ELISA)   test
(Wiener Lab, Argentina).
The DNA extraction from whole blood was performed
with the E.Z.N.A.® Blood DNA Kit (Omega Bio-tek, Inc.,
USA). The DNA obtained was quantified with a NanoDrop™
2000 spectrophotometer (Thermo Scientific) and was
visualized  in  2%  agarose  gels  through  the  Gel  Doc  XR
(Bio-Rad) system. Finally, Quantity One software (Bio-Rad)
was employed to quantify the images.
The primers utilized for MTHFR C677T polymorphism
identification were the following: F: 5'TGAAGGAGAAGG
TGTCTGCGGGA3', R: 5'AGGACGGTGCGGTGAGTG3'
and  F2:  5’GCAGGGAGCTTTGAGGCTGAC3’.  Utilizing
β-actin as control, the samples were run under the following
conditions: at 94°C×3' (1 cycle); (at 94°C×1' and at 60°C×1'
and at 72°C×30'' (35 cycles), at 72°C×7' (1 cycle) and at 4°C
(4).
In relation to the enzymatic studies, digestion assay of the
PCR products was performed with the HINFI enzyme
(Promega), 228-bp bands were obtained when the T allele was
absent and 172-bp patterns when the CT polymorphism was
present (Fig. 1).
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Fig. 1: Enzymatic digestion with the HINFI enzyme.  Column 1: Sample 34, Column 2: Sample 34, Column 3: Sample 38,
Column  4:  Sample 41, Column 5: Sample 42, Column 6: Sample 43, Column 7: Sample 44, Column 8: Sample 45,
Column 9: Sample 46, Column 10: Sample 47, Column 11: Sample 48, Column 12: Sample 49, Column 13: Sample 50,
Column 14: Sample 51, Column 15: Positive control (C+), Column 16: Negative control (C-)
This protocol was approved by the Ethical and Research
Committee of the ISSSTE, Mexico City. In accordance with
the National Ministry of Health and the Declaration of
Helsinki (Fortaleza, Brazil), this study was classified as zero
risk to participants, because it did not involve procedures in
addition to those strictly necessary for the highest care
standard in the institution’s Hemodialysis Unit. All patients
signed the informed consent of the hospital.
Statistical analysis: Quantitative variables were expressed as
mean±standard deviation (SD) and qualitative variables in
frequency and percentage. Differences among nominal
conditions were evaluated by the Mann-Whitney U-test. For
establishing connection between different parameters,
Spearman test was used. Regression, log-linear analysis and
receiver operating characteristic (ROC) curves were conducted
to evaluate, whether Hcy levels or the presence of the MTHFR
C677T polymorphism exerted an influence on disease
evolution. Cox regression and Kaplan-Meier tests were
performed to evaluate the Hcy levels influence on survival. In
all cases, p<0.05 was considered statistically significant. All
tests were performed with the SPSS ver. 23 statistical software
program (IBM SPPS 23, USA).
RESULTS
From 53 initially selected patients on hemodialysis, full
data was available for 27 of these, who were included in this
study. Seventeen (62.96%) patients were males and 10
(37.03%) females. The mean age of the patients was
57.9±14.82 years (range, 25-87 years). Three (11.11%)
patients  answered  to  be  physically  active,  nine  (33.33%)
were active smokers, 15 (55.55%) referred usual alcohol
ingestion   and   two   (7.4%)   confirmed   a   drug   addiction
only.
Regarding the underlying disease, 22 (81.48%) patients
had hypertension, 6 (22.22%) had T2DM and five (18.51%)
were diabetic, hypertensive and dyslipidemic. the general
characteristics of the patients and comorbidities are showed in
Table 1. It is interesting to note that besides the patients with
known T2DM, three more had hyperglycemia during the
study. On the other hand, within the patients with a lipid
disorder, seven (25.92%) had mixed dyslipidemia. The
laboratory characteristics of the population are depicted in
Table 2. Of the 27 samples analyzed, five (18.51%) presented
the C677T polymorphism. Although, the Hcy levels showed
a trend to be higher in the presence of C677T than in those
patients without this SNP (40.8 vs 32.4 µmol LG1) there was
no statistical difference.
Six (22.22%) patients died, 4 men and 2 women, being the
causes of death: Acute myocardial infarction (AMI) (N = 4),
septic shock (N = 1) and pneumonia (N = 1). The Mann-
Whitney U-test revealed a significant difference in the
following situations: Creatinine between genders (p = 0.027)
and age between those who were alive or  dead  after  1  year
(p = 0.042).
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Within the data of all the patients, the Spearman test
demonstrated   an   expected   positive   correlation   between 
age   and   urea   (r2   =   0.476,   p  =  0.046),  age  and  BUN
(r2 = 0.471, p = 0.048) and between BUN and urea (r2 = 0.614,
p = 0.007), but Hcy did not show any significant correlation
with the evaluated  laboratory  tests.  On  the  other  hand, 
triglycerides had positive significant correlations with glucose
(r2 = 0.605, p = 0.01), HbA1c (r2 = 0.614,  p  =  0.011),  urea 
(r2  =  0.620, p = 0.008) and age (r2 = 0.483, p = 0.049).
Of particular concern was the result of age as the sole
significant prognostic variable for the “death” with the
regression analysis (p = 0.046) as well as with the ROC curve
(p = 0.03, [95%CI 0.001-0.306]). The log-linear analysis did
not demonstrate any association between the presence either
of obesity or SNP and the mortality of our patients.
By performing the same analysis separated for men and
women, neither Hcy nor the presence of the C677T
polymorphism were identified to be a mortality predictive
factor. Finally, the survival analysis for Hcy levels was not
significant.
DISCUSSION
Patients with end-stage renal disease (ESRD) are at a high
risk of adverse cardiovascular events. In this respect, the data
of this survey points out the severity of comorbidities, for
example,  the  high  positive correlation between triglycerides
Table 1: General characteristics of the patients and comorbidities
Variables Values
Age (years)a 53.5 ± 15.8
Body mass index (kg mG2)a 30.4 ± 4.9
Hyperuricemiab 5 (18.51)
Hypercholesterolemiab 8 (29.62)
Hypertriglyceridemiab 7 (25.92)
Hyperglycemiab 9 (33.33)
Obesityb 10 (37.03)
a: Mean±Standard Deviation, b: Number (%)
Table 2: Laboratory characteristics of the patients
Variables Mean ±SD
Blood urea nitrogen (mg dLG1) 91.9 ± 48.4
Cholesterol (mg dLG1) 188.4 ± 91.2
CKD-EPI (mL/min/1.73 m2) 5.1 ± 2.4
Creatinine (mg dLG1) 10.9 ± 4.3
Glucose (mg dLG1) 161.3 ± 87.9
HbA1c (%) 8.3 ± 3.0
Homocysteine (µmol LG1) 36.6 ± 27.4
Triglycerides (mg dLG1) 191.5 ± 142.5
Urea (mg dLG1) 151.3 ± 36.2
Uric acid (mg dLG1) 6.3 ± 1.1
CKD-EPI: Chronic kidney disease-epidemiology collaboration
and other metabolic parameters (HbA1c, glucose and urea)
suggests a high prevalence of metabolic syndrome (cause
ESRD) and uremic syndrome (clinical manifestation of
ESRD), in both cases it is mandatory to establish a more
intensive treatment.
There is controversial data about the role of Hcy, with
some authors pointing out that it comprises an important risk
factor for cardiovascular morbidity and mortality in patients
undergoing dialysis16-18 and others saying the contrary19-20.
In a study by Selhub on patients under dialysis with and
without CVD, the serum Hcy level was significantly high in
patients with CVD compared with patients without this health
issue (37.2 vs. 24 µmol LG1)21. In this study, the mean serum
Hcy level of our patients was similar to those of the first
group; in contrast, Tamadon et al.22 published lower. The
explanation for the difference between the values reported by
Tamadon and ours is not clear, but we can exclude T2DM, in
that the percentage of affected patients with this disease was
similar: 32.33 vs. 37.03%. A possible variable of differences
in Hcy levels trends after initiating the replacement treatment
might be the dialysis technique, because even the type of
membrane demonstrates a decisive role23. It is also noteworthy
that Hcy is higher in patients with peritoneal disease than in
patients on dialysis24. An excellent review of the associations
between serumHcy level and outcomes in patients with ESRD
as well as the associations between genetic polymorphisms of
MTHFR, MTR, MTRR, GCP2, RFC1 and TCN2 and Hcy
concentrations in patients with ESRD has been conducted by
Wu et al.25 In that review, from 20 studies (years 1995-2006),
15 showed a higher risk for CVD in case of
hyperhomocysteinemia and five showed a protective effect
Following this line, some contrasting works about Hcy as a
cardiovascular risk factor in CKD are shown in Table 3.
Another study showed that supraphysiologic levels of
cofactors in Hcy metabolism, including folic acid, 15 mg/day,
vitamin B6, 100 mg/day and vitamin B12, 1 mg/day, could
maintain the serum Hcy level lower than its normal serum
level21. However, in the absence of any thrombotic events,
there is no definite indication for the treatment of
hyperhomocysteinemia30. Despite the existence of some
strategies for the reduction of the serum Hcy level in patients
with CKD, including folate and vitamin supplementation31, the
findings of this survey add to the growing body of evidence
from clinical trials exhibiting the lack of any significant effect
regarding the serum Hcy level and mortality in these patients32.
Additional studies, including prospective dietary intervention
trials, could provide much needed information on these
associations with survival.
Table 3: Studies of homocysteine as a risk factor in chronic kidney disease
Authors Effects Comments
Qin et al.26 Positive This meta-analysis included 3886 patients
Jardine et al.27 Negative 10,951 participants in total
Pena and Claro28 Negative This work analyzed the papers from Qin et al.26 and Jardine et al.27
Levi et al.29 Positive A historical prospective study on 3602 subjects
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About the MTHFR C677T genotype, a meta-analysis of
Gao et al.33 concluded that this polymorphism may be
associated with an elevated risk for CVD in ESRD, especially
among Asians. In contrast, our results did not put the presence
of MTHFR C677T genotype as a strong determinant for
mortality, at least in a short follow up of 1 year. Since the
patients with this SNP showed a trend to have higher levels of
Hcy, belonging to the range of moderately elevated34,
probably, in this situation, the beneficial effect of reducing
Hcy could be confirmed in a more expanded population
leading to an expected shrinkage of the standard deviation and
reaching significant statistical difference p<0.05.
Taken together, these findings need to be interpreted
within the context of several inherent limitations, for example,
a handful of factors may contribute to the Hcy changes. For
example, the Log (tHcy) is directly related to the use of
diuretics35. In this regard, the drug doses were not supervised;
secondly, Hcy is influenced by dietary habits, which were
deliberately not recorded. Third and last, the effect of other
Hcy-lowering agents, such as vitamin B12, was not analyzed
in the current study. These limitations may have compromised
our findings. Notwithstanding, the major strength of this study
is the evaluation not only of serum Hcy but also of the
presence of the MTHFR C677T genotype, which offers a
better approach to understand the implication over a clinical
prognosis than with any of them alone.
CONCLUSION
Based on the result of this study and on previous reports,
the effect of Hcy on mortality in hemodialysis patients is not
strong enough to consider it as cardiovascular risk factor in
ESRD patients, but probably those patients with the MTHFR
C677T genotype have proclivity to show Hcy levels in range
of moderately elevated or severe hyperhomocysteinemia and
could be impacted positively with a supplemental and
nutritional intervention program to keep Hcy within normal
range. This last supposition needs further research.
SIGNIFICANCE STATEMENTS
Patients subjected to hemodialysis are under the toxic
effects of hyperhomocysteinemia, present in about 85-90% of
these subjects. Hyperhomocysteinemia causes are varied and
include a genetic component in which single nucleotide
polymorphisms (SNP) play a key role. The results of this study
confirms that Hcy does not represent a specific mortality risk
in end stage renal disease patients treated with hemodialysis
but the role of the presence of MTHFRC677T SNP that
induces levels in range of moderately elevated or severe
hyperhomocysteinemia has still to be elucidated.
ACKNOWLEDGMENTS
Authors thank to Samuel Huehuecóyotl de Vas Velasco of
the Clinical Laboratory of the “Dr. Darío  Fernández  Fierro”
General Hospital, ISSSTE, Mexico City and Maggie Brunner
M.A., for her excellent help with the English style correction.
This project was partially funded by Ciprés Grupo Médico
S.C. (CGM), grant: 2016-05.
REFERENCES
1. Gonzalez-Devia,      J.      and      H.      Mendieta-Zeron,
2013.  [Hyperhomocysteinemia/homocystinuria  as
cardiovascular  risk  factor  children  and  adolescents].
Rev. Costarric. Cardiol., 15: 15-22, (In Spanish).
2. Veyrat-Durebex,  C.,  H.  Blasco,  J.  Crinier,  C.  Vayne
and  P.  Emond  et  al.,  2013.  [Investigation  of
hyperhomocysteinemia]. Ann. Biol. Clin., 71: 517-525,
(In French).
3. Guilland,  J.C.,  A. Favier, G.P. de Courcy, P. Galan and
S. Hercberg, 2003. [Hyperhomocysteinemia: An
independent risk factor or a simple marker of vascular
disease?.  1.  Basic  data].  Pathol.  Biol.,  51:  101-110,
(In French).
4. Malinowska,   J.,   J.   Kolodziejczyk   and   B.   Olas,
2012. The disturbance of hemostasis induced by
hyperhomocysteinemia; the role of antioxidants. Acta
Biochim. Pol., 59: 185-194.
5. Abais, J.M., M. Xia, G. Li, T.W.B. Gehr, K.M. Boini and
P.L. Li, 2014. Contribution of endogenously produced
reactive oxygen species to the activation of podocyte
NLRP3 inflammasomes in hyperhomocysteinemia. Free
Radical Biol. Med., 67: 211-220.
6. Ma,    Y.,    L.    Li,    X.B.    Geng,    Y.    Hong    and
X.M. Shang et al., 2016. Correlation between
hyperhomocysteinemia and outcomes of patients with
acute    myocardial    infarction.    Am.    J.    Therapeut.,
23: e1464-e1468.
7. Deng, D. and A. Forbes, 2015. Cardiovascular risk factors
in patients on dialysis. Nephrol. Nurs. J., 42: 45-50.
8. Saifan, C., E. El-Charabaty and S. El-Sayegh, 2013.
Hyperhomocysteinemia and vascular access thrombosis in
hemodialysis patients: A retrospective study. Vasc. Health
Risk Manage., 9: 361-364.
9. Anan,   F.,   T.   Masaki,   Y.   Umeno,   H.   Yonemochi,
N. Eshima, T. Saikawa and H. Yoshimatsu, 2007.
Correlations between homocysteine levels and
atherosclerosis in Japanese type 2 diabetic patients.
Metabolism, 56: 1390-1395.
10. Kuller, L.H. and R.W. Evans, 1998. Homocysteine,
vitamins    and    cardiovascular    disease.    Circulation,
98: 196-199.
11. McIlroy, S.P., K.B. Dynan, J.T. Lawson, C.C. Patterson
and A.P. Passmore, 2002. Moderately elevated plasma
homocysteine,  methylenetetrahydrofolate  reductase
genotype and risk for stroke, vascular dementia and
Alzheimer    disease    in    Northern    Ireland.    Stroke,
33: 2351-2356.
93
J. Med. Sci., 17 (2): 89-94, 2017
12. Prieto, K., R. Garcia, J. Bernal and M. Bermudez, 2009.
[Descriptive analysis of homocysteine levels, C699T,
C1080T and 844Ins68pb polymorphisms of CBS,
MTHFR C677T and other cardiovascular risk factors in a
Colombian population with acute coronary syndrome].
Univ. Med., 50: 322-334, (In Spanish).
13. Sanchez-Urbina,       R.,       C.       Galaviz-Hernandez,
J.A.     Sierra-Ramirez,     H.     Rangel-Villalobos     and
R. Torres-Saldua et al., 2012. Methylenetetrahydrofolate
reductase gene 677CT polymorphism and isolated
congenital   heart   disease   in   a   Mexican   population.
Rev. Espanola Cardiol. (Engl. Edn.), 65: 158-163.
14. De   Vecchi,   A.F.,   C.   Novembrino,   M.C.   Patrosso,
D. Cresseri and S. Ippolito et al., 2003. Effect of
incremental doses of folate on homocysteine and
metabolically related vitamin concentrations in
nondiabetic  patients  on  peritoneal  dialysis.  ASAIO  J.,
49: 655-659.
15. Undas,    A.,    T.B.    Domagala,    M.    Jankowski    and
A. Szczeklik, 1999. Treatment of hyperhomocysteinemia
with folic acid and vitamins B12 and B6 attenuates
thrombin generation. Thromb. Res., 95: 281-288.
16. Jakovljevic, B., B. Gasic, P. Kovacevic, Z. Rajkovaca and
T. Kovacevic, 2015. Homocystein as a risk factor for
developing   complications   in   chronic   renal   failure.
Mater. Sociomed., 27: 95-98.
17. Balsam, A., M.M. El-Kossi, R. Lord and A.M. El-Nahas,
2009.  Cardiovascular  disease  on  hemodialysis:
Predictors of atherosclerosis and survival. Hemodial. Int.,
13: 278-285.
18. Heinz, J., S. Kropf, C. Luley and J. Dierkes, 2009.
Homocysteine as a risk factor for cardiovascular disease
in patients treated by dialysis: A meta-analysis. Am. J.
Kidney Dis., 54: 478-489.
19. Sahinarslan,  A.,  G.  Guz,  K.  Okyay,  R.  Mutluay  and
R. Yalcin et al., 2008. Prognostic value of troponin T and
homocysteine in patients with end-stage renal disease.
Arch. Turk. Soc. Cardiol., 36: 382-387.
20. Akgul, A., A. Bilgic, S. Sezer, Z. Arat, F.N. Ozdemir and
M. Haberal, 2008. Low total plasma homocysteine level
in relation to malnutrition, inflammation and outcome in
hemodialysis patients. J. Renal Nutr., 18: 338-346.
21. Selhub, J., 1999. Homocysteine metabolism. Ann. Rev.
Nutr., 19: 217-246.
22. Tamadon,  M.,  L. Jamshidi, A. Soliemani, R. Ghorbani,
F. Malek and M. Malek, 2011. Effect of different doses of
folic acid on serum homocysteine level in patients on
hemodialysis. Iran. J. Kidney Dis., 5: 93-96.
23. Dessi,  M.,  G. Di Giovamberardino, M. Pieri, A. Noce,
R. Zenobi, N. Di Daniele and A. Pastore, 2015. Influence
of  dialysis  techniques  and  alternate  vitamin
supplementation on homocysteine levels in patients with
known    MTHFR    genotypes.    Clin.    Exp.    Nephrol.,
19: 140-145.
24. Harmankaya,  O.,  N.  Akalin,  H.  Akay,  Y.  Okuturlar,
K. Erturk, H. Kaptanogullari and H. Kocoglu, 2015.
Comparison of risk factors for cardiovascular disease in
hemodialysis  and  peritoneal  dialysis  patients.  Clinics,
70: 601-605.
25. Wu, C.C., C.M. Zheng, Y.F. Lin, L. Lo, M.T. Liao and
K.C. Lu, 2012. Role of homocysteine in end-stage renal
disease. Clin. Biochem., 45: 1286-1294.
26. Qin,   X.,   Y.   Huo,   C.B.   Langman,   F.    Hou    and
Y. Chen et al., 2011. Folic acid therapy and
cardiovascular disease in ESRD or advanced chronic
kidney disease: A meta-analysis. Clin. J. Am. Soc.
Nephrol., 6: 482-488.
27. Jardine, M.J., A. Kang, S. Zoungas, S.D. Navaneethan
and T. Ninomiya et al., 2012. The effect of folic acid
based homocysteine lowering on cardiovascular events in
people  with  kidney  disease:  Systematic  review  and
meta-analysis. Br. Med. J., Vol. 344. 10.1136/bmj.e3533.
28. Pena, J. and J.C. Claro, 2014. [Is folic acid effective for
the prevention of cardiovascular events in patients with
advanced or terminal chronic kidney disease?]. Rev. Med.
Chile, 142: 636-645, (In Spanish).
29. Levi, A., E. Cohen, M. Levi, E. Goldberg, M. Garty and
I. Krause, 2014. Elevated serum homocysteine is a
predictor of accelerated decline in renal function and
chronic kidney disease: A historical prospective study.
Eur. J. Internal Med., 25: 951-955.
30. Stenvinkel, P., R. Pecoits-Filho and B. Lindholm, 2003.
Coronary artery disease in end-stage renal disease: No
longer a simple plumbing problem. J. Am. Soc. Nephrol.,
14: 1927-1939.
31. Tayebi-Khosroshahi,  H.,  R.  Dehgan,  B.  Habibi  Asl,
A. Safaian, F. Panahi, R. Estakhri and B. Purasgar, 2013.
Effect of omega-3 supplementation on serum level of
homocysteine in hemodialysis patients. Iran. J. Kidney
Dis., 7: 479-484.
32. Bostom, A.G., M.A. Carpenter, J.W. Kusek, A.S. Levey
and L. Hunsicker et al., 2011. Homocysteine-lowering
and cardiovascular disease outcomes in kidney transplant
recipients: Primary results from the folic acid for vascular
outcome reduction in transplantation trial. Circulation,
123: 1763-1770.
33. Gao, X.H., G.Y. Zhang, Y. Wang and H.Y. Zhang, 2014.
Correlations of MTHFR 677C>T polymorphism with
cardiovascular disease in patients with end-stage renal
disease: A meta-analysis. PLoS ONE, Vol. 9.
10.1371/journal.pone.0102323.
34. Cybulska, B. and L. Klosiewicz-Latoszek, 2015.
Homocysteine-is it still an important risk factor for
cardiovascular disease? Kardiol. Pol., 73: 1092-1096.
35. Bates, C.J., M.A. Mansoor, J. van der Pols, A. Prentice,
T.J. Cole and S. Finch, 1997. Plasma total homocysteine
in a representative sample of 972 British men and women
aged 65 and over. Eur. J. Clin. Nutr., 51: 691-697.
94
